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Next to α-synuclein deposition, microglial activation is a prominent pathological feature in the substantia nigra (SN)
of Parkinson’s disease (PD) patients. Little is known, however, about the different phenotypes of microglia and how
they change during disease progression, in the SN or in another brain region, like the hippocampus (HC), which is
implicated in dementia and depression, important non-motor symptoms in PD.
We studied phenotypes and activation of microglia in the SN and HC of established PD patients (Braak PD stage
4–6), matched controls (Braak PD stage 0) and of incidental Lewy Body disease (iLBD) cases (Braak PD stage 1–3)
that are considered a prodromal state of PD. As recent experimental studies suggested that toll-like receptor 2
(TLR2) mediates α-synuclein triggered microglial activation, we also studied whether TLR2 expression is indeed
related to pathology in iLBD and PD patients.
A clear α-synuclein pathology-related increase in amoeboid microglia was present in the HC and SN in PD. Also,
morphologically primed/reactive microglial cells, and a profound increase in microglial TLR2 expression were
apparent in iLBD, but not PD, cases, indicative of an early activational response to PD pathology. Moreover, TLR2 was
differentially expressed between the SN and HC, consistent with a region-specific pattern of microglial activation.
In conclusion, the regional changes in microglial phenotype and TLR2 expression in primed/reactive microglia in the
SN and HC of iLBD cases indicate that TLR2 may play a prominent role in the microglial-mediated responses that could
be important for PD progression.
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receptor 2Introduction
Parkinson’s disease (PD) is a progressive neurodegener-
ative disorder that affects 1–2% of the elderly popula-
tion [1]. Besides classical motor problems that are
related to nigro-striatal dopamine deficits [2], also non-
motor symptoms are common in PD. These include
autonomic dysfunction, sensory, sleep and cognitive dis-
turbances as well as neuropsychiatric alterations, that* Correspondence: amw.vandam@vumc.nl
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unless otherwise stated.strongly affect the quality of life of PD patients [3-8].
An important pathological hallmark of PD is the pres-
ence of α-synuclein inclusion bodies, i.e. Lewy bodies
(LBs) and Lewy neurites (LNs), which spread in a pre-
dictable manner throughout the brain [9]. While their
spatiotemporal development parallels the appearance of
non-motor and motor symptoms [10], little is known
about changes in microglial activation, another promin-
ent pathological feature of PD [11-13].
Under neurodegenerative conditions, microglial cells
readily transform from a ramified morphology into
amoeboid-shaped cells. They acquire specific functions,
including phagocytosis, and can secrete a variety of factors,Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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(ROS) and trophic factors [14,15]. While in vitro and ex-
perimental animal studies had demonstrated that α-
synuclein can trigger microglial activation, in vivo imaging
and post-mortem immunohistochemical studies have now
established the presence of amoeboid microglia and pro-
inflammatory mediators in the substantia nigra (SN) in PD
[11,16-20]. Interestingly, increased densities of amoeboid
microglia were also observed in the olfactory bulb (OB)
of PD patients and in a mouse model for PD (1-methyl-
4-phenyl-1,2,3,6-tetrahydropyridine) [21,22,23,24]. Thus,
microglial activation occurs also outside the SN, where it
coincides with α-synuclein deposition. In contrast to the
SN, it is not associated with neuronal cell death [23]. These
observations agree with novel views on microglia as a het-
erogeneous cell population that may exert brain region-
dependent functions [13,25,26,27]. As such, microglia are
thought to contribute to local inflammatory responses, not
in a uniform, but rather in a brain region-specific manner.
Based on their morphology and receptor expression,
different microglial phenotypes have been identified in
the brain [28,29]. These include cells with a small cell
body and many thin ramifications, called ramified
microglia, cells with a larger, less round cell body and
thick ramifications, called primed and reactive microglia,
and cells with hardly or no ramifications, which are clas-
sified as amoeboid microglia [29]. Besides these different
morphologies, that likely reflect different functionalities
[30-32], also toll-like receptors (TLR) have attracted
considerable attention. TLR activation of microglia forms
the primary response against a wide array of pathogens
[33,34], including aggregated proteins, e.g. α-synuclein
[34,35]. Activation of the TLR pathway increases the ex-
pression of various pro-inflammatory cytokines, like IL-6,
IL-1 and TNF-α [36,37].While earlier evidence has been
obtained in the field of Alzheimer’s disease (AD) [38,39]
and Multiple Sclerosis (MS) [40], recent studies have im-
plicated TLRs also in the pathogenesis of PD [41-44]. In
support of this, TLR-deficient mice are less vulnerable to
MPTP toxicity and show decreased microglial activation
in the SN after MPTP treatment [45], while (Thy1)-
[A30P] α-synuclein transgenic mice show a significant up-
regulation of TLR2 [46]. Moreover, the oligomeric form of
α-synuclein acts as an endogenous agonist of TLR2 on
microglia where it stimulates pro-inflammatory cytokine
expression [47]. As this effect is not induced by TLR3 and
TLR4, the TLR2 subtype is considered highly specific for
the neuroinflammatory response of microglia in PD [41].
Thus far, studies on microglia in PD have focused
mainly on the SN. Based on the spatiotemporal develop-
ment of α-synuclein pathology over different brain re-
gions during PD progression, also microglial activation
may differ between brain regions. In the present study,
we investigated differences in microglial phenotype, i.e.in ramified, primed/reactive and amoeboid subtypes, and
compared the SN to the hippocampus (HC), a brain re-
gion that has been implicated in the cognitive deficits
and depressive symptoms frequently present in PD
[48,49]. We studied tissue of clinically diagnosed and
neuropathologically verified PD patients (Braak PD stage
4–6) [50], age- and gender-matched control subjects
(Braak PD stage 0) and incidental Lewy body disease
(iLBD) cases (Braak PD 1–3), that did not have clinical
PD symptoms but displayed α-synuclein deposition at
autopsy and can therefore be considered a prodromal
state of PD [51]. Moreover, as α-synuclein can stimulate
microglia through TLR2, we further investigated whether
TLR2 is expressed in the SN and HC of iLBD and PD
cases in relation to α-synuclein deposition.
Materials & methods
Post-mortem brain tissue
Human post-mortem brain tissue was obtained from the
Netherlands Brain Bank (NBB, Amsterdam, The Netherlands)
or from the department of Pathology, VU University
Medical Center (VUmc, Amsterdam, The Netherlands).
In compliance with all local ethical and legal guidelines,
informed consent for brain autopsy and the use of brain
tissue and clinical information for scientific research
was given by either the donor or the next of kin. The
SN and HC were included from 14 clinically diagnosed
and neuropathologically verified PD patients (Braak PD
stage 4–6). Of these, 8 SN and 9 HC were included from
patients who had suffered from dementia during PD
progression (PDD). Furthermore, from iLBD cases (Braak
PD stage 1–3), 9 SN and 6 HC were studied. The control
group consisted of healthy subjects without neurological
or psychiatric disease and without LB pathology (Braak
PD stage 0), of which 13 SN and 9 HC were studied. Sec-
tions from all donors were included in the studies per-
formed. Importantly, in 75% of the cases, the HC and SN
tissue was obtained from the same patient, ruling out the
possibility that regional differences are due to ‘between
patient’ differences. All three groups were matched for
gender and age; control subjects ranged from 62–92, iLBD
cases from 56–91 and PD patients ranged from
59–96 years of age. Furthermore, all subjects were con-
trolled and matched for post-mortem delay and cerebro-
spinal fluid pH value. Donors who died of sepsis, or stroke
were excluded (Table 1).
The Braak neurofibrillary tangles (NFT) stages and Aβ
scores for AD, and LBs/LNs containing α-synuclein
score for PD were provided by the NBB and were based
upon careful neuropathological evaluation of disease-
relevant brain areas by established and qualified neuro-
pathologists [52]. The density and distribution of LBs/
LNs, NFT and Aβ plaques were determined based on
Bodian silver staining and immunohistochemical analysis
Table 1 Clinical and neuropathological information of all included subjects
Braak staging
C# Sex Age PMD (hrs) AD (NFT / Aβ) PD (α-syn) D Region Cause of death
1 F 92 7:00 1A 0 NDC HC + SN Acute death, pulmonary emboly
2 M 88 4:23 2A 0 NDC HC + SN Gastro-intestinal bleeding
3 F 84 6:55 1O 0 NDC HC + SN Myelodysplasia
4 M 82 5:10 1O 0 NDC HC + SN Unknown
5 M 62 7:20 1O 0 NDC HC + SN Unknown
6 F 77 2:55 1B 0 NDC SN Pulmonary metastasis
7 M 84 5:35 1A 0 NDC SN Heart failure
8 M 75 4:15 1B 0 NDC SN Respiratory insufficiency
9 M 71 6:00 2(−) 0 NDC SN Respiratory insufficiency
10 M 81 7:55 2O 0 NDC SN Renal insufficiency
11 F 78 7:30 2(−) 0 NDC SN Heart failure
12 M 79 6:00 1B 0 NDC SN Metastates prostate and lung cancer
13 F 83 8:00 1O 0 NDC SN Respitatory insuffisiency
14 F 83 3:20 1B 0 NDC HC Legal Euthanasia
15 F 84 4:45 1O 0 NDC HC Heart failure
16 F 85 5:19 2B 0 NDC HC Natural death, pulmonary disease
17 M 78 <17:00 1O 0 NDC HC Natural cause,
18 F 82 5:10 2O 2 iLBD HC + SN Heartfailure
19 M 86 4:00 2B 1 iLBD HC + SN Respiratory insufficiency
20 M 56 5:00 0(−) 2 iLBD HC + SN Pneunomia
21 F 91 4:50 (−) 1 iLBD HC + SN Exhaustion, colon carcinoma
22 M 84 7:20 1B 3 iLBD HC + SN Prostate cancer
23 F 82 7:00 1O 3 iLBD SN Pneunomia
24 F 85 4:40 2A 1 iLBD SN Dehydration
25 F 93 <10:00 0(−) 1 iLBD SN Unknown
26 F 78 <10:00 0(−) 1 iLBD SN Unknown
27 M 87 10:20 1A 1 iLBD HC Pneunomia, heart failure
28 M 83 4:50 1A 4 PDD HC + SN Heartfailure
29 F 59 9:35 1A 4 PD HC + SN Shock due to blood loss in digestive tract
30 F 90 4:50 1B 4 PDD HC + SN Unknown
31 M 84 9:00 1A 5 PDD HC + SN Pneunomia and dehydration
32 F 70 7:05 2B 6 PDD HC + SN Haematemesis by oesophagitis
33 F 87 5:25 2B 6 PDD HC + SN Pneunomia
34 M 73 5:35 1A 5 PDD HC + SN Direct cause unknown (morphine)
35 M 83 5:15 1B 6 PDD HC + SN Pneunomia
36 F 84 7:25 2B 5 PD HC + SN Old age, shortness of breath
37 F 96 7:10 1B 5 PD HC + SN Old age
38 M 86 5:10 2B 5 PD HC + SN Heartfailure
39 M 71 5:50 1A 6 PD HC + SN Respiratory failure
40 M 86 5:35 1O 4 PD SN Aspiration pneumonia
41 M 80 7:05 1B 6 PDD SN Unknown, possibly urine tract infection
42 F 83 6:05 1O 4 PDD HC Cachexia by dementia, infarction
43 M 83 6:35 1B 6 PDD HC Pneunomia
D, clinical diagnosis; PMD, post mortem delay; NFT, neurofibrillary tangles; Aβ amyloid beta; α-syn, alpha synucleine; NDC, non-demented control subject; iLBD,
incidental Lewy Body Disease cases; PD, Parkinson’s disease; PDD, Parkinson’s disease with dementia; HC, hippocampus, SN, substantia nigra.
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hyperphosphorylated tau (Clone AT8, Pierce, Rockford,
IL) and Aβ (Clone 6 F/3D, DAKO, DakoCytomation
BV), respectively. The AD Braak stages and scores were
further matched between control subjects, iLBD cases and
PD patients, ruling out any possible differences in micro-
glial activation due to AD pathology. The clinicopatholog-
ical data of the patients including the Braak staging for PD
and AD of all donors is summarized in Table 1.
Tissue processing
At autopsy, brain regions were dissected and immersion-
fixed in 4% formaldehyde for four weeks and subsequently
embedded in paraffin. From the paraffin blocks of the
HC and the ventral mesencephalon, which included the
SN pars compacta, 10 micrometer (μm) thick sections
were cut with a microtome, mounted on positively-
charged glass slides (Menzel-Glaser SuperFrost Plus,
Braunschweig, Germany) and dried in a stove overnight
at 37°C before immunohistochemical staining.
Immunohistochemistry
Sections were heated in a stove for one hour at 56°C, be-
fore they were deparaffinized in xylene and rehydrated
through a graded series of ethanol (100%, 96%, 90% and
70%, respectively) and distilled water. For subsequent
antigen retrieval, sections were rinsed in 10 mM Tris
Buffer (pH 9.0) containing 1 mM EDTA (Tris-EDTA)
and placed in preheated Tris-EDTA buffer in a steamer
at 90-99°C for 30 minutes. For α-synuclein staining,
antigen retrieval was performed using pretreatment with
98% formic acid (Sigma, Steinheim, Germany) for 10 min
at room temperature (RT). After pretreatment, the sec-
tions were RT, rinsed in Tris-buffered saline (TBS, pH 7.6)
and incubated for 20 min in TBS containing 0.3% H2O2
and 0.1% sodiumazide to block endogenous peroxidase ac-
tivity. Non-specific binding was blocked with 5% non-fat
dried milk in TBS containing 0.5% Triton (TBS-T, pH 7.6;
blocking solution) for 30 min at RT. Subsequently, sec-
tions were incubated overnight at 4°C with mouse anti-
CD68, mouse anti-α-synuclein, goat anti-TLR2 or rabbit
anti-Ionized calcium binding adaptor molecule 1 (Iba1)
antibodies diluted in blocking solution (details on the pri-
mary antibodies are specified in Table 2). Sections were
then washed in TBS and incubated for 2 hr at RT in theTable 2 Primary antibodies used for single labeling
Antigen Species Final dilution Source
Human CD68 Mouse 1:500 DAKO, clone KP1
Human α-synuclein Mouse 1:2000 BD-Bioscience, 610786
Human Iba1 Rabbit 1:4000 WAKO chemicals
Human TLR2 Goat 1:2000 R&D systemsappropriate dilutions of biotinylated goat anti mouse
IgG’s, goat anti rabbit IgG’s or donkey anti goat IgG’s
(1:400; Jackson ImmunoResearch Laboratories Inc., West
Grove, Pennsylvania, USA) followed by horse radish per-
oxidase (HRP)-labeled avidin-biotin complex (ABC com-
plex, 1:400; Vector Laboratories, Burlingame, CA, USA)
in TBS-T for 1 hr at RT. Iba1 and CD68 staining were
visualized using 3,3-diaminobenzidine (DAB, Sigma, St.
Louis, USA) and counterstained with heamatoxylin, while
TLR2 and α-synuclein immunostaining were visualized
using DAB-nickel as a chromogen, and counterstaining
was performed with Fast red. After dehydration in graded
ethanol solutions, sections were cleared in xylene and
coverslipped in Entellan (Merck).
Immunofluorescence
For double-immunofluorescent labeling of glial cells and
TLR2 expression, sections were co-incubated with com-
binations of antibodies against microglia, i.e. CD68, Iba1,
or astrocytes, i.e. GFAP, and against TLR2. Antigen re-
trieval was performed by pretreating the sections with
Tris-EDTA (pH 9.0) and all antibodies (TLR2/Iba1,
TLR2/CD68, TLR2/GFAP) were diluted in blocking so-
lution, as indicated above. After an overnight incubation
at 4°C, the sections were washed and subsequently incu-
bated for 2 h at RT with the appropriate Alexa Fluor
488 or Alexa Fluor labeled 594 IgG’s (1:400, Jackson
Immunoresearch, Westgrove, PA, USA) (see Table 3 for
information on antibodies and conjugates). After wash-
ing, sections were coverslipped with Vectashield and
later examined using a confocal microscope (Leica TSC-
SP2-AOBS; Leica Microsystems, Wetzlar, Germany).
Microglial phenotypes: identification criteria for ramified,
primed/reactive and amoeboid microglia
Classification of ramified and amoeboid microglia morph-
ology was performed as described in detail before [23].
Microglial cells were identified by positive CD68 immuno-
reactivity (IR) [53]. Both microglial subtypes are character-
ized by cytoplasmic staining, but the ramified microglial
celltype can be distinguished by its small cell body and
thin, radially projecting processes. Amoeboid microglia
are characterized by a densely CD68-stained cell body






Human Iba1 Rabbit 1:2000 WAKO chemicals DoaR-AF488 1:400
Cow GFAP Rabbit 1:2000 DAKO DoaR-AF488 1:400
Human CD68 Mouse 1:300 DAKO, clone KP1 DoaM-AF488 1:400
Human TLR2 Goat 1:500 R&D systems DoaG-AF594 1:400
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ramified microglia as cells having a small circular body
with highly ramified processes. Iba1 positive microglia
with a primed/reactive phenotype display a bigger and less
round cell body with thicker and sometimes less ramifica-
tions compared to the ramified phenotype. Iba1 positive
amoeboid microglia show an amoeboid cell body with, at
most, two unramified processes, or they are completely
devoid of them [29].
Semi-quantitative analyses of microglial cells, a-synuclein
deposition and TLR2 expression
For semi-quantificative analysis, the numbers of CD68
positive amoeboid microglial cells and α-synuclein
immunopositive deposits (LBs and LNs) present in the
HC pyramidal cell layers, i.e. CA4, CA3, CA2 and CA1,
were counted per CA area (region of interest, ROI,
0.5 mm2) at a 10 × 3.3 magnification. For standardization
purposes, hippocampal sections were collected around
the anterior-to-midlevel of the HC of every subject,
and only when large DG and CA subregions were both
present. For the SN, the area of interest was larger (ROI,
1.5 mm2) and quantification was performed at the ana-
tomical levels of the oculomotor nerve. Microglial cells
were counted at a 10 × 3.3 magnification; hence, these data
are presented as number of cells per 1.5 mm2. Semi-
quantitative analysis of TLR2 and Iba1 IR was based on
the amount of IR per ROI. To this end, pictures were
taken at a 10×3.3 magnification and on these a standard-
ized threshold procedure was used that distinguished
background from specific IR. Subsequently, the amount of
specific IR was measured within the defined ROI, and
expressed as percentages of TLR2 and Iba1 IR per ROI.
Semi-quantitative analyses were performed unbiased using
CellF Olympus Soft Imaging Solutions GmbH software,
version 3.1 (Tokyo, Japan). All data were expressed as
mean +/− standard error of the mean (SEM).
Statistical analysis
All statistical analyses were performed with the SPPS
package version 20.0 (Statistical Product and Service
Solutions, Chicago, IL, USA). The normal distribution of
the data was investigated using the Kolmogorov-Smirnov
test. When normally distributed (Iba1), statistical analysis
for between group effects was performed with an inde-
pendent sample T-test. When a normal distribution was
absent (CD68, TLR2, α-synuclein), statistical analyses
were executed with the non-parametric Kruskal-Wallis
test to examine main group effects between control sub-
jects, iLBD cases and PD patients. Subsequently, Mann–
Whitney U tests were performed as post-hoc tests to
assess between group effects. Statistical analyses for the
different subregions of the HC within the same cases were
performed with the non-parametric paired Wilcoxon test.Significance was set at 0.05 with Bonferroni corrections
for multiple testing where applicable.
Results
α-Synuclein pathology and increased numbers of CD68
positive amoeboid microglia in the SN
We first examined the SN that is classically affected in
PD. In the SN of control subjects and iLBD cases, numer-
ous neuromelanin-containing and pigmented dopamin-
ergic neurons were present (Figure 1). No α-synuclein
pathology was observed in the SN of controls, while in the
iLBD cases, few α-synuclein positive deposits were de-
tected (Figure 1a, b respectively; Figure 2a). In contrast,
PD patients showed extensive loss of neuromelanin-
containing, dopaminergic neurons in the SN, and the
number of LBs and LNs was significantly increased com-
pared to both control and iLBD cases (Figure 1c; Figure 2a;
PD vs Ctr/iLBD p < 0.01; Ctr n = 13, Mean = 0 ± 0; iLBD
n = 9, Mean = 7 ± 6.2; PD n = 14, Mean = 29.2 ± 4.9). Fur-
thermore, in control subjects, the large majority of CD68
positive microglia had long and fine processes, indicative
of their ramified phenotype, with only a small number of
cells displaying an amoeboid morphology (Figure 1d). The
number of amoeboid microglia was significantly increased
in iLBD cases compared to control subjects (Figure 1e;
Figure 2b; iLBD vs Ctr p = 0.002; Ctr Mean = 13.2 ± 4.1;
iLBD Mean = 46.6 ± 12.0). PD patients showed numerous
and widespread CD68 positive amoeboid microglia in the
SN, significantly more than in the iLBD and in control
cases (Figure 1f; Figure 2b; PD vs iLBD p = 0.035, PD vs
Ctr p = 0.000; PD Mean = 80.6 ± 12.9).
α-Synuclein pathology is apparent in the hippocampal
CA2 subregion of PD patients
Next, α-synuclein pathology was examined in the HC.
No α-synuclein IR was present in the HC of control and
iLBD cases (shown for CA2; Figure 3a, b). In contrast,
α-synuclein positive deposits were prominent in the HC
of PD and PDD patients and especially concentrated in
the pyramidal layer CA2, where their numbers were sig-
nificantly increased compared to the CA2 of control
and iLBD cases (Figure 3c; Figure 4b; PD vs Ctr/iLBD
p < 0.01; Ctr n = 9, Mean 0 ± 0; iLBD n = 6, Mean 0.5 ±
0.5; PD n = 14 Mean 24.5 ± 7.4) and also compared to
the other pyramidal regions CA1, CA3 and CA4 within
PD patients (Figure 3c; Figure 4a; significantly different
between all regions p < 0.05; and CA2 vs CA1/CA3/CA4
p = 0.001; CA2 Mean = 24.5 ± 7.4; CA1 Mean = 0.8 ± 0.5;
CA3 Mean = 4.9 ± 2.5; CA4 Mean = 3.1 ± 1.9).
Increased number of CD68 positive amoeboid microglia
in the HC of iLBD cases and PD patients
In the pyramidal layer of the HC of control subjects,
iLBD cases and PD patients, CD68 positive, ramified
Figure 1 α-Synuclein pathology and CD68 immunopositive microglia in the substantia nigra (SN) of control subjects, iLBD cases and
PD patients. Brown staining depicts the melanin-containing, dopaminergic neurons that degenerate during PD. (a) No intraneuronal α-synuclein
immunoreactivity (IR)(purple) was observed in the SN of control subjects, (b) some intraneuronal α-synuclein IR was found in the SN of iLBD
cases (arrow), and (c) widespread intraneuronal and neuritic α-synuclein IR is observed in the SN of PD patients (LBs: arrows, LNs arrowhead);
(d) a control subject showing some CD68 positive ramified microglial cells (purple, arrow), (e) an iLBD case showing prominent CD68 positive
ramified (arrow) and amoeboid (concave arrowhead) microglial phenotypes, and (f) a PD patient, showing few CD68 positive ramified (arrow),
but many more amoeboid microglial phenotypes (concave arrowhead); bar (a-f) = 100 μm.
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but CD68 positive amoeboid microglia were clearly
more present in PD patients (Figure 3f ) compared to
control and iLBD cases (Figure 3d, e), especially in
the CA2 and CA3 region (shown for CA2 Figure 5d;
PD vs Ctr/iLBD p = 0.007; Ctr Mean = 13 ± 2.9; iLBD
Mean = 12.1 ± 2.5; PD Mean = 37.2 ± 7.2). Interestingly,
in control and iLBD cases, a significantly higher number
of CD68 positive amoeboid microglia was present in
the CA2 and CA3 as compared to other subregions
(Figure 5a, b; Ctr: CA1 vs CA2/CA3/CA4 p < 0.02, CA3
vs CA4 p = 0.025; CA1 Mean = 2.7 ± 0.8; CA2 Mean =
12.9 ± 2.9; CA3 Mean = 14.8 ± 1.9; CA4 Mean = 8.5 ±1.9; iLBD: CA1 vs CA2/CA3/CA4 p = 0.027, CA4 vs
CA2/CA3 p < 0.05; CA1 Mean = 4.0 ± 1.0; CA2 Mean =
12.2 ± 2.5; CA3 Mean = 12.7 ± 2.0; CA4 Mean = 7.2 ±
1.4). This subregion-specific difference in CD68 positive
amoeboid microglia was larger in PD patients, with the
highest numbers present in the CA2 region (Figure 5c;
PD: CA1 vs CA2/CA3/CA4 p < 0.01, CA4 vs CA2/CA3
p < 0.01, CA3 vs CA2 p = 0.278 n.s.; CA1 Mean = 7.0 ±
1.2; CA2 Mean = 37.2 ± 7.2; CA3 Mean = 32.5 ± 6.5;
CA4 Mean = 17.5 ± 4.5). Based on the α-synuclein and
CD68 observations in the HC, our subsequent analyses
of Iba1 and TLR2 immunoreactivity focused mainly on
the CA2 region.
Figure 2 Quantification of α-synuclein pathology and CD68 immunopositive amoeboid microglia density in the substantia nigra (SN)
of control subjects, iLBD cases and PD patients. (a) A significant increase was present in α-synuclein deposits in PD patients compared to the
control and iLBD cases (*p < 0.001 vs Ctr, iLBD), and (b) a significant increase in CD68 positive amoeboid microglia was present in PD patients
compared to control subjects and iLBD cases (*p < 0.01 vs Ctr; *p < 0.05 vs iLBD). The number of CD68 positive amoeboid microglia in iLBD cases
was also significantly higher compared to control subjects (#p < 0.01 vs Ctr). Data represent mean ± SEM.
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In addition to CD68, Iba1 IR was used to determine
the overall presence of microglial cells and to classify
different phenotypes in the SN and HC. In all subjects,
Iba1 positive ramified microglia displayed a small circu-
lar cell body with highly ramified processes. This pheno-
type was the most prominent one in control subjects
(Figure 6a, d). In iLBD cases, additional primed/reactive
Iba1 positive microglial cells were present, with a bigger
and less round cell body and thicker ramifications as
compared to the ramified phenotype (Figure 6b, e).
These primed/reactive microglia were also present in PD
patients with the addition of a few Iba positive amoeboid
microglia displaying at most two unramified processes,
or none at all (Figure 6c, f ).
A significant increase was found in total Iba1 density in
the SN of PD patients relative to controls (Figure 6a, c;
Figure 7a; PD vs Ctr p = 0.03; Ctr Mean = 6.0 ± 0.6; PD
Mean = 7.7 ± 0.5), but not in iLBD cases compared to
controls. Total Iba1 density did not differ between sub-
regions of the HC (not shown) nor between control
subject, iLBD cases and PD patients (shown for CA2
Figure 6d-f; Figure 7b; Ctr Mean = 7.7 ± 0.7; iLBD
Mean = 8.3 ± 1.2; PD Mean = 7.2 ± 0.4).
Increased TLR2 expression in the SN and HC of iLBD cases
In control subjects, only very few TLR2 positive cells and
processes were observed in the SN and HC (Figure 8a, a’;
Figure 9a, a’). In iLBD cases, however, TLR2 IR was prom-
inent and widespread throughout the SN and total
HC, and significantly increased relative to control subjects
in both regions (Figure 8b, b’; Figure 10; iLBD vs Ctr
p = 0.000; Ctr Mean = 0.7 ± 0.2; iLBD Mean = 5.7 ± 0.9;
shown for CA2 Figure 9a, b, b’; Figure 11d; iLBD vs Ctr
p = 0.018; Ctr Mean = 0.7 ± 0.3; iLBD Mean = 2.8 ± 0.7).
This upregulation in the HC was not CA2 specific, but
observed in all hippocampal CA regions (Figure 11a-c).However, within iLBD cases, TLR2 IR was significantly
higher in the CA2, CA3 and CA4 as compared to CA1
(Figure 11b; CA1 vs CA2/CA4/CA3 p = 0.028; iLBD
CA1 Mean = 1.5 ± 0.4; CA2 Mean = 2.8 ± 0.7; CA3 Mean =
3.8 ± 0.9; CA3 Mean = 3.6 ± 0.8).
In PD, TLR2 expression was significantly decreased
compared to iLBD cases in both the SN and HC (SN
Figure 8a-c, a’-c’; Figure 10; iLBD vs PD p = 0.018;
iLBD Mean = 5.7 ± 0.9; PD Mean = 3.1 ± 0.5; HC/CA2
Figure 9a-c, a’-c’; Figure 11d; iLBD vs PD p = 0.013; PD
Mean = 0.8 ± 0.2). However, TLR2 IR in the SN of PD pa-
tients remained significantly elevated compared to control
subjects (Figure 10; Ctr vs PD p = 0.000; Ctr Mean = 0.7 ±
0.2; PD Mean = 3.1 ± 0.5). In contrast, in all pyramidal
layers of the HC of PD patients, TLR2 IR was low and
comparable to the level of control subjects, and TLR2
IR only in the CA2 was slightly but significantly higher
relative to the other CA regions (Figure 11c; CA2 vs CA1/
CA4/CA3 p < 0.02; CA2 Mean = 0.8 ± 0.2; CA1 Mean =
0.5 ± 0.2; CA4 Mean = 0.5 ± 0.2; CA3 Mean = 0.7 ± 0.2).
Colocalization of TLR2 with microglial cells in HC and SN
To determine which cells express TLR2, double labeling
revealed that TLR2 was not expressed by GFAP positive
astrocytes in the SN or HC (Figure 12). However, clear
colocalization was found between Iba1 positive primed/
reactive microglia and TLR2 IR, in almost all TLR2 posi-
tive cells in the HC and SN (Figure 13). Finally, to deter-
mine whether amoeboid microglia also express TLR2,
double labeling for TLR2 and CD68 revealed that indeed
TLR2 IR was present in CD68 positive amoeboid micro-
glia in the SN of PD patients (Figure 14).
Discussion
In the present study, we investigated different microglial
phenotypes, and TLR2 expression in relation to the
α-synuclein pathology in the SN and HC of iLBD cases,
Figure 3 α-Synuclein pathology and CD68 immunopositive microglia in the hippocampal CA2 region of control subjects, iLBD cases
and PD patients. (a, b) α-synuclein IR in the CA2 of control and iLBD cases is absent compared to (c) PD patients (purple, LBs: arrow, LNs:
arrowhead); (d) a control subject showing CD68 positive ramified microglial cells (arrow), (e) an iLBD case showing CD68 positive ramified (arrow)
and few microglial cells with an amoeboid (concave arrowhead) phenotype and (f) a PD patient, showing CD68 positive ramified (arrow) and
several amoeboid (concave arrowhead) microglial cells; bar (a-f) = 100 μm.
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http://www.actaneurocomms.org/content/2/1/90considered a prodromal state of PD, and of established
PD patients. Clear differences were present in microglial
phenotypes between the SN and HC. The amoeboid type
was found to parallel the prominent α-synuclein path-
ology in the SN and hippocampal CA2 subregion in PD.
TLR2 expression was strongly increased in primed/react-
ive microglia of the iLBD cases. Unexpectedly, in PD
patients, TLR2 IR remained upregulated in the SN,
but was reduced to control levels in the HC. Thus,
TLR2 expression in microglia occurs in a disease stage-
dependent manner that differs between the HC and SN.
The high levels in iLBD cases and not in PD patients
suggest an early activational response to the develop-
ment of PD pathology. As such, our results confirm,
for the first time in human brain, recent in vitro andexperimental studies indicating that TLR2 is an import-
ant player in the neuroinflammatory responses during
PD progression. A general scheme representing the dif-
ferences in microglial phenotypes and TLR2 expression
in the SN and HC during disease progression in PD, as
represented by the Braak PD stages, is summarized in
Figure 15.
In addition to its well established pattern in the SN, α-
synuclein pathology was prominent in the HC, a brain
region involved in cognition and affective symptoms that
have been implicated in the non-motor symptomatology
and frequent dementia and depression in PD patients
[5,7]. In line with a previous study, α-synuclein path-
ology in the HC was largely confined to the CA2 sub-
region [54]. We observed that this selective vulnerability
Figure 4 Quantification of α-synuclein pathology in the hippocampus (HC) of control subjects, iLBD cases and PD patients. (a) Significant
differences were present in α-synuclein deposits between all pyramidal subregions of the HC in the PD patients (*p < 0.05). The CA2
region was affected the most relative to the other hippocampal subregions (#p < 0.01). (b) Comparison of α-synuclein pathology in CA2
between the three patient cohorts showed a significant increase in the PD patients compared to control and iLBD cases (*p < 0.01 vs
iLBD, Ctr). Data represent mean ± SEM.
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http://www.actaneurocomms.org/content/2/1/90was independent of whether PD patients had been diag-
nosed with dementia. Although only few studies have so
far implicated CA2 in PD symptomatology, the selective
localization of α-synuclein pathology to this subregion
and its recent involvement particularly in social forms ofFigure 5 Quantification of CD68 immunopositive amoeboid microglia
patients. (a-c) Numbers of CD68 positive amoeboid microglia were signifi
control subjects, (b) iLBD cases and (c) PD patients (*p≤ 0.02 vs CA2, CA3,
CA4 of control subjects (#p < 0.05 vs CA4), and in (b, c) CA2 and CA3 comp
respectively vs CA2, CA3). (d) Comparison of all groups together resulted in
microglia in the PD patients relative to control and iLBD cases (data shownmemory may hold some promise for a better interpret-
ation of the clinical symptoms [48,55,56].
While general microgliosis has been repeatedly dem-
onstrated in several pathological sites in PD, including
the SN, HC and OB, little was known about the brainin the hippocampus (HC) of control subjects, iLBD cases and PD
cantly lower in CA1 compared to all other pyramidal layers in (a) the
CA4). A significant increase was observed in (a) CA3 compared to
ared to CA4 in (b) iLBD cases and (c) PD patients (#p < 0.05, #p≤ 0.01,
a significant increase in the numbers of CD68 positive amoeboid
for CA2, *p < 0.01 vs iLBD, Ctr). Data represent mean ± SEM.
Figure 6 Iba1 immunopositive microglia in the substantia nigra (SN) and hippocampal CA2 region of control subjects, iLBD cases and
PD patients. (a,b) Widely distributed Iba1 positive ramified microglial cells (arrow) in a control subject, (c,d) an iLBD case and (e,f) a PD patient.
Iba1 positive microglia are present with ramified (arrow), primed/reactive (concave arrowhead) and amoeboid (short arrow) phenotypes;
bar (a-f) = 50 μm.
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between presymptomatic and established PD [23,57,58].
In both the SN and HC of PD patients, the number of
activated, CD68 positive, amoeboid microglial cells was
increased. As in the HC, this increase was present espe-
cially in the CA2 and CA3, notably in close proximity
to α-synuclein pathology; this suggests that an inflam-
matory response occurs to these neuropathological
alterations, similar to the SN. Strikingly, increases in
amoeboid microglia in the SN were observed in iLBD
cases too, in which little, if any, DAergic cell loss was
present postmortem, nor had any clinical motor symp-
toms been apparent during these patients’ lives [51].
This is of importance since it contributes to the debate
whether microglial activation is merely a reaction toneuronal cell death or whether these cell respond to
other (early) pathological events [13] and therefore ac-
tively participate in the pathological processes before cell
death occurs, as suggested by our observations in the
SN and HC. In the HC however, amoeboid microglia
were not increased in iLBD cases, consistent with the
fact that the HC at this stage (Braak PD 1–3) is still de-
void of any α-synuclein deposits. This is different from
the SN that already shows prominent α-synuclein
deposits by then. It indicates that α-synuclein deposits
may trigger a morphological transition into amoeboid
microglia before actual cell loss becomes apparent and is
in line with observations in the anterior olfactory nu-
cleus [23], and with experimental studies showing that
α-synuclein can trigger microglial activation [20,41,47].
Figure 7 Quantification of Iba1 immunoreactivity (IR) in the substantia nigra (SN) and hippocampal CA2 region of control subjects,
iLBD cases and PD patients. (a) A significant increase was present in Iba1 IR in the SN of PD patients relative to control subjects (*p < 0.05
vs Ctr); (b) no significant difference was present in the CA2. Data represent mean ± SEM.
Figure 8 TLR2 immunopositive cells in the substantia nigra (SN) of control subjects, iLBD cases and PD patients. (a) Control subject
showing few TLR2 positive cells (arrow), (b) an iLBD case showing widespread and numerous TLR2 positive cells (arrows) and (c) a PD patient,
showing moderate numbers of TLR2 positive cells (arrows), (a’-c’) represent higher magnifications of (a-c); bar (a-c, a’-c’) = 100 μm.
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Figure 9 TLR2 immunopositive cells in the hippocampal CA2 region of control subjects, iLBD cases and PD patients. (a) A control
subject showing few TLR2 positive cells (arrow), (b) an iLBD case showing widespread and numerous TLR2 positive cells (arrow) and (c) a PD
patient, showing again very few TLR2 positive cells (arrow), similar to controls, (a’-c’) represent higher magnifications of (a-c); bar
(a-c) = 100 μm; (a’-c’) = 50 μm.
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tive microglia was not different between the subject
groups, whereas in the SN an increase was observed in
PD patients compared to control subjects. The pheno-
type of the Iba1 positive ramified microglia had changed
into primed/reactive Iba1 positive microglia in the HC
and SN of both the iLBD cases and PD patients, notably
irrespective of the presence of α-synuclein pathology.
Together, this suggests that Iba1 positive ramified micro-
glia may respond to a stimulus other than accumulated
or aggregated α-synuclein, that likely is independent of
the local SN or HC environment and is already present
during the prodromal stage. Possibly, the primed micro-
glial morphology represents microglia, which are in a
more sensitive state to subsequent stimuli, commonlyreferred to as ‘second hit’ [30,31,59]. Although the exact
nature of such a stimulus awaits future studies, oligo-
meric or soluble forms of α-synuclein are attractive can-
didates in this respect.
To further characterize the spatio-temporal changes in
microglial phenotypes during PD progression, and to
identify possible underlying mechanisms, we focused
on TLR2, an important member of the TLR family that
was recently implicated in microglial activation in PD
[41,46]. To rule out any possible differences in microglial
activation and TLR2 expression due to AD pathology,
NFT and Aβ scores were matched between control sub-
jects, iLBD cases and PD patients. We found TLR2 to be
strongly increased in the SN and HC of iLBD cases, but
not in PD patients. Recent in vitro and in vivo animal
Figure 10 Quantification of TLR2 immunoreactivity (IR) in the
substantia nigra (SN) of control subjects, iLBD cases and PD
patients. A significant increase was found in TLR2 IR in the SN of
iLBD cases compared to control subjects and PD patients (#p < 0.05
vs Ctr, PD). In PD patients, TLR2 IR was significantly increased in the
SN compared to the SN of control subjects (*p = 0.0001 vs Ctr). Data
represent mean ± SEM.
Figure 11 Quantification of TLR2 immunoreactivity (IR) in the hippoc
No significant differences in TLR2 IR were present between the different hi
TLR2 IR was found in CA2, CA3 and CA4 compared to CA1 within iLBD cas
found at lower levels that were significantly increased in CA2 relative to th
compared to CA4 (#p < 0.02 vs CA4). (d) When TLR2 IR in all four hippocam
the iLBD cases compared to control subjects and PD patients (data shown
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vate microglia via TLR2 and thereby stimulate NFκB-me-
diated pro-inflammatory cytokine production [41,47].
Also, microglial cells treated with α-synuclein signifi-
cantly enhance their TLR2 expression [35]. Since we
found the Iba1 positive primed/reactive phenotype to
express TLR2 particularly [29], this suggests that prim-
ing of microglial cells, possibly by α-synuclein oligomers,
could involve TLR2. The upregulation of TLR2 we found
in iLBD cases will then most likely reflect an early
activational response of microglia to e.g. α-synuclein
oligomers, prior to the development of extensive PD
pathology, i.e. when neuronal cell death is still barely
present. Furthermore, there only seemed to be a topical
relation between α-synuclein accumulation and TLR2
expression in the SN. In the HC, TLR2 expression was
widespread and not confined to the CA2 region, suggest-
ing that the factors causing TLR2 upregulation are
present in a more widespread distribution in the HC,
consistent with a role for e.g. oligomeric forms of
α-synuclein. This hypothesis is supported by previous
in vitro studies where pre-conditioning microglia with
abnormal α-synuclein strongly affected their subsequent
TLR2 mediated response [44]. A subsequent challenge
(‘second hit’), like actual α-synuclein deposits and/orampus (HC) of control subjects, iLBD cases and PD patients. (a)
ppocampal regions within control subjects, (b) a significant increase in
es (*p < 0.05 vs CA2, CA3, CA4). (c) In PD patients TLR2 IR was overall
e CA1, CA3 and CA4 (*p < 0.02 vs CA1, CA3, CA4) and also in CA3
pal subregions was taken together, a significant increase was found in
for CA2, *p < 0.02). Data represent mean ± SEM.
Figure 12 Absence of colocalization of TLR2- and GFAP immunopositive astrocytes in the substantia nigra (SN) and hippocampal CA2
region. (a-f) Representative images of confocal laser scanning microscopy failed to reveal any colocalization (c, f) between GFAP (a, d; green)
and TLR2 (b, e; red) in the (a-c) SN and (d-f) CA2 of iLBD cases; bar (a-f) = 20 μm.
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change the primed phenotype into an amoeboid one, as
we observed. This is also in line with the increase in
amoeboid microglia in CA2 and CA3, where α-synuclein
deposits are abundant.Figure 13 Colocalization of TLR2- and Iba1 immunopositive primed/r
CA2 region of iLBD cases. (a-f) Representative images of confocal laser s
primed/reactive microglia (a, d; green) and TLR2 (b, e; red) in the (a-c) SNIn the HC of PD patients, TLR2 IR was reduced to the
level of control subjects, whereas in the SN, its expres-
sion remained significantly increased. This difference in
expression may reflect the absence of a continuous
stimulus, like neuronal loss, that is not apparent in theeactive microglia in the substantia nigra (SN) and hippocampal
canning microscopy revealed colocalization (arrow; c, f) of Iba1 positive
and (d-f) CA2 of iLBD cases; bar (a-f) = 10 μm.
Figure 14 Colocalization of TLR2- and CD68 immunopositive amoeboid microglia in the substantia nigra (SN) of PD patients. (a-c)
Representative images of confocal laser scanning microscopical images revealed colocalization (arrow; c) of CD68 positive amoeboid microglia
(a; green) and TLR2 (b; red) in the SN of PD patients; bar (a-f) = 10 μm.
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hippocampal atrophy has been observed by MRI [60,61],
neuronal loss is not present in the HC of PD patients
[62]. Interestingly, in the CA2, TLR2 expression was still
significantly elevated. This also supports the idea that a
second stimulus, e.g. α-synuclein deposits, after an early
pathological stimulus in iLBD cases, may further trigger
TLR2 and microglial activation in PD.
Although the primary role of microglia may be to clear
toxic proteins and thereby protect neurons, TLR-2 medi-
ated activated microglia have taken on different or add-
itional roles in chronically diseased brains. So far, most
studies interpret microglial activation by TLR2 as a clas-
sical microglial activation profile that gives rise to the se-
cretion of mainly pro-inflammatory cytokines [41,63,64].
However, other studies suggest that receptors like TLR2
can be considered as a ‘gateway’ in their functionality
that can influence the balance between e.g. phagocytic
and pro-inflammatory microglial activity [63]. A high ex-
pression level of such receptors would then promote an
alternative route of activation (e.g. an anti-inflammatoryFigure 15 Schematic summary of the different patterns of
α-synuclein pathology and microglial phenotypes and activation
(Iba1, CD68, TLR2) in the hippocampal CA2 region and SN during
disease progression in PD.profile) and phagocytosis, whereas low levels could induce
a pro-inflammatory state. It is as yet unknown whether
this concept would also apply to TLR2 expression in PD,
but it could have important implications for therapy [65].
The final consequences of the TLR2 activation we report
here may however, also depend on additional factors, like
the assembly state of the protein ligand, the duration of
stimulation and the repertoire of co-receptor and adaptor
proteins that interact with TLR2 [41].
In summary, we report region-specific differences in the
expression of different microglial phenotypes in the SN, a
classically affected brain region involved in motor symp-
toms in PD, and in the HC, a brain region relevant for
some of the non-motor symptoms, like dementia, in PD.
Besides differential changes in microglial activation and
phenotypes in the SN and hippocampal CA2 of PD pa-
tients, TLR2 is strongly expressed in primed/reactive
microglia in iLBD cases, considered a prodromal state of
PD, in both the HC and SN. Understanding how microglia
responses and activation differs between regions and how
they change during disease progression will improve our
understanding of the role of microglia in neurodegenera-
tion and neuroprotection in general, and of their role in
PD pathology in particular. Since neuroinflammatory re-
sponses are in principle modifiable, such approaches may
help to develop new drugable targets or adjunctive therap-
ies for PD-related symptoms.Abbreviations
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